AC
ALDX icon

Apogem Capital’s Aldeyra Therapeutics ALDX Stock Holding History

Apogem Capital’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-85,091
Closed -$454K – 4
2022
Q3 		$454K Sell
85,091
-64,256
-43% -$386K 0.45% 71
2022
Q2 		$596K Buy
149,347
+45,305
+44% +$156K 0.54% 62
2022
Q1 		$462K Buy
104,042
+17,312
+20% +$69K 0.32% 105
2021
Q4 		$347K Buy
86,730
+30,077
+53% +$229K 0.23% 123
2021
Q3 		$497K Buy
56,653
+10,922
+24% +$100K 0.32% 109
2021
Q2 		$518K Buy
45,731
+9,421
+26% +$113K 0.33% 104
2021
Q1 		$431K Sell
36,310
-19,511
-35% -$225K 0.29% 112
2020
Q4 		$383K Buy
+55,821
New +$392K 0.25% 116

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Apogem Capital's ALDX Position: Q4 2022 in Review

Apogem Capital sold out of Aldeyra Therapeutics (ALDX) in Q4 2022, closing a stake of 85,091 shares — an estimated $454K sold.

Apogem Capital first reported a position in ALDX in Q4 2020 and held it in 8 quarters. The position peaked at $596K in Q2 2022. 96 funds tracked by Wall St. Rank hold ALDX as of Q4 2022.

  • Apogem Capital reported no remaining Aldeyra Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Apogem Capital sold 85,091 Aldeyra Therapeutics shares in Q4 2022, an estimated $454K.
  • Apogem Capital first reported a position in Aldeyra Therapeutics in Q4 2020 and held it in 8 quarters.
  • Apogem Capital's Aldeyra Therapeutics position peaked at $596K in Q2 2022.
  • 96 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q4 2022.

Based on Apogem Capital's 13F filing for Q4 2022, filed 13 Feb 2023.